3rd AC21 Research Festival

From Genes to Patients:
New Perspectives on Personalised Medicines

International One Day Symposium Wednesday 5th July, 2006

Medical Teaching Centre, Warwick Medical School, University of Warwick, UK

cpt@warwick.ac.uk

---

The Symposium was supported by a Award.

---

 

Fig. 1. Commission on human medicines chair Professor Sir Gordon Duff presents

the best poster award to Dr Mariluz Rodriguez, N Ireland

---

Symposium outline

A major opportunity to improve treatment of patients arises from the fact that treatment response can be influenced by individual differences in tissue regulation and drug effectiveness. Differences in treatment response may for example arise from genetic and resulting proteomic differences in drug transporters, receptors and in pathways for drug action. Occurrence of adverse drug reactions (ADRs) can also be associated with genetic differences linked to poor drug metabolism. Pharmacogenetic and pharmacoproteomic profiling thus carries the potential to improve earlier selection of effective drug treatments, to reduce incidence of ADRs and to reduce pressures on medical services. The aim of the symposium was to consider ways in which recent developments in genomics and in proteomics can applied to effective personalised medicine profiling in clinical practice and to consider issues important in implementing into practice the necessary health technology innovations.

 

 

 

 

Fig. 2. Top left: Professor Robert Freedman, Head Biological Sciences, University of Warwick, introducing the first session; top centre: Dr Duncan mchale, Pfizer; top right: Dr Kevin Cheeseman, Astrazeneca; lower left, Dr guy Barker, warwick HRI; lower left, Professor Jan dumanski, university of birmingham, alabama & university of uppsala.

---

Speakers, discussants and chairs: click on links for information on speakers and their abstracts

• Professor Vilhjálmur Árnason, Chair of the Centre for Ethics, University of Iceland, Reykjavik Abstract

• Dr Guy Barker, Warwick HRI

• Dr Christopher Bridle, Health Psychology, Warwick

• Francesco Cappuccio, Professor of Cardiovascular Medicine & Epidemiology, Warwick Medical School
• Professor Yvonne Carter, Dean, Warwick Medical School
• Professor Ruth Chadwick, Director, ESRC Centre for Economic and Social Aspects of Genomics, Lancaster
• Dr Kevin Cheeseman, Discovery Medicine & Epidemiology, AstraZeneca R&D
• Professor Sir Gordon Duff, Chair, Commission on Human Medicines
• Professor Jan Dumanski, Molecular Oncology, Rudbeck Laboratory, Uppsala University
• Professor Ralph Edwards, WHO Collaborating Centre for International Drug Monitoring, Uppsala Abstract
• Dr David Elsy PhD, Withers & Rogers LLP
• Dr Robin Ferner, Director of the West Midlands Centre for Adverse Drug Reaction Reporting
• Professor Robert Freedman, Head of Biological Sciences, University of Warwick
• Dimitris Grammatopoulos, Director, Molecular Diagnostics Laboratory, UHCW
• Professor John Hearn, Pro-Vice Chancellor (Academic & International), University of Sydney Abstract
  Maj Hulten, Professor of Medical Genetics, University of Warwick
• Professor Magnus Ingelman-Sundberg, Molecular Toxicology, Institute of Environmental Medicine. Karolinska Institute, Stockholm Abstract
• Christopher McCabe, Professor of Health Economics, Warwick Medical School
• Dr Duncan McHale, Pharmacogenetics Division, Pfizer
• Professor Louis Niessen, Institute for Medical Technology Assessment, Erasmus University Abstract
• Dr Sandosh Padmanabhan, BHF Glasgow Cardiovascular Research Centre Abstract
• Donald Singer, Professor of Clinical Pharmacology & Therapeutics, Warwick Medical School
• Margaret Thorogood, Professor of Epidemiology, Warwick Medical School
• Dr Frank Vince, Coventry
• Professor Victor Zammit, Director, Clinical Sciences Research Institute, Warwick Medical School

fig. 3. top left: Dr David Elsy (l), Withers & rogers LLP, Dr Frank vince, Coventry & professor donald singer (r), symposium chair, University of Warwick; top centre: Professor Vilhjálmur Árnason, Reykjavik; top right: professor ruth chadwick, cardiff; lower left: professor ralph edwards, who, uppsala; lower centre: professor magnus ingelman-sundberg, karolinska, stockholm; lower right: professor Sir gordon duff, chair, commission on human medicines.

---

Fig. 4. Poster sessions

 

click on the links to view the abstracts of the posters presented on the day of the symposium

1. Allele and genotype frequencies of DPYD*2A and TYMS in a Turkish population. 

 

3. Gene therapy using VEGF-E/human PlGF chimeric genes for therapeutic angiogenesis in experimental animal model  

 

4. Neutralization of hepatocyte growth factor inhibits human cytomegalovirus replication in human lung fibroblast

5. Application of biochip array technology to the non-invasive qualitative simultaneous detection of DNA alterations in colorectal cancer. 

6. The Magic Tag Kit: Immobilisation and Screening of Bioactives 

 

7. Association between SNPs in Adenosine Receptor 2a (ADORA2a) and Adverse Drug Reactions (ADRs) in Methotrexate Treated Rheumatoid Arthritis Patients 

8. Role of oxidant stress in human endothelial cells

9. Reduced risk for endothelial dysfunction in diabetes: is correcting hyperglycaemia enough? 

10. Relationship of alpha-1-antitrypsin serum levels and genetic variants in patients with phenotypic alpha-1-antitrypsin deficiency 

 

11. Health Technology Assessment (HTA) of Non-Invasive RhD Testing 

 

12. Exploring patients’ and healthcare professionals’ views of pharmacogenetic testing

Emily A Fargher1, Charlotte Eddy2, Katherine Payne1, Karen Tricker1, Rachel A Elliott3, Faieza Qasim4, Ian Bruce4, Jon Shaffer5, Christopher Griffiths5, Kieran Moriarty6, Cath Pearson6, and William Newman1&2.

1North West Genetics Knowledge Park, The University of Manchester, Manchester, UK; 2Clinical Genetics, St Mary’s Hospital, Manchester, UK; 3School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, UK; 4Central Manchester & Manchester Children's University Hospitals NHS Trust, Manchester, UK; 5Salford Royal Hospitals NHS Trust, Salford, UK; 6Bolton Hospitals NHS Trust, Bolton, UK.

 

14. Taking the fight to the superbugs – searching for new antibiotics 

 

15. Preliminary Phenotyping Studies in the TARGET Project: Thiopurine Methyltransferase (TPMT) Measurements and Azathioprine Metabolite Profiling 

Local Organizing Committee

Professor Wendy Currie, Warwick Business School
Dr Dimitris Grammatopoulos, Molecular Diagnostics
Pam Magee, Chief Pharmacist
Professor Christopher McCabe, Health Economics
Dr Daniel Mitchell, Pharmacogenomics
Dr Teresa Pawlikowska, Primary Care
Professor Donald Singer, Clinical Pharmacology & Therapeutics Symposium Leader
Professor Margaret Thorogood, Epidemiology
Dr Junlong Zhang, Molecular Endocrinology

---

Key topics included:

• Genetic targets: CYP enzymes, drug transporters; receptors, cell signalling

• Genetic methods: genotyping; gene mapping; SNP vs. CNP studies

• Proteomic approaches to drug discovery

• Clinical cohort phenotyping and follow up

• Pharmacovigilance platforms: expert systems and cross-cultural issues

• Bio-informatics

• Ethical considerations

• Intellectual Property and Patents

• Health economics of implementing personalised gene testing

• Patients’ & users’ perspectives

• Role of regulatory authorities

• Role of biotechnology industry

• Role of pharmaceutical industry

• Role of Small to Medium-sized Enterprises [SMEs]

---

Who attended?

This symposium was of interest to:

• Biotechnology industries

• Clinicians

• Ethicists

• Experts in Intellectual Property and Patents

• Health economists

• Health media

• Pharmaceutical professionals

• Pharmacists and other interested health professionals

• Policy makers

• Regulatory Authorities

• Scientists interested in genetics, genomics, proteomics, glycobiology and new therapeutic targets

• Statisticians, include experts in risk analysis

---

Shakespeare Social Programme

---

Associated International Research Festival

AC21 3rd Biennial International Forum, July 4-6, 2006: See Research Festival link for further information on Symposia on Health Wealth & Nutrition, Nanotechnology, Mathematics and Beyond, Sustainable Manufacturing, Global HE Research, Corporate Responsibility, English in Higher Education

---

Clinical Pharmacology

 

International symposium Home Page

Progress on Personalizing Medicines

25th September 2008

 

 

 

 

 

fig. 6. University of Sydney Pro-Vice Chancellor Professor John Hearn discussing Stem Cell Therapy

Podcasts

Personalised Medicines Programme

International Scientific Board

Local Organising Committee

Clinical Pharmacology Newsletters

integrated personalised medicines - ipermed